
|Articles|December 14, 2022
Readying Biologics for Commercialization
Author(s)Thermo Fisher Scientific
Given the risks and opportunities inherent in drug development, choosing the right late-phase strategy to optimize timelines and capacity, while remaining flexible enough for changing market conditions, presents a significant challenge to companies developing and commercializing biopharmaceutical products. This piece highlights new technologies and strategies to reduce risk and execute consistently.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Achieving Real Impact Navigating the Data and Regulatory Barriers to AI Adoption in Bio/pharma
2
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
3
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
4
BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints
5
